Clicky

eFFECTOR Therapeutics, Inc.(EFTR)

Description: eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.


Keywords: Cancer Biopharmaceutical Biology Breast Cancer Cancer Treatment Molecular Biology Lung Cancer Antineoplastic Drugs Non Small Cell Lung Carcinoma Nsclc Signal Transduction Pembrolizumab Metastatic Non Small Cell Lung Cancer Protein Biosynthesis Anti Viral Therapy Defense Advanced Research Projects Agency Kinase 1

Home Page: effector.com

EFTR Technical Analysis

142 North Cedros Avenue
Solana Beach, CA 92075
United States
Phone: 858 925 8215


Officers

Name Title
Dr. Stephen T. Worland Ph.D. CEO, Pres & Director
Mr. Michael Byrnes M.B.A. Chief Financial Officer
Dr. Siegfried Reich Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Davide Ruggero Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Douglas Warner M.D. Chief Medical Officer
Dr. Mayank J. Gandhi M.D. Chief Bus. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.408
Price-to-Book MRQ: 1.5445
Price-to-Sales TTM: 5.2547
IPO Date: 2021-08-26
Fiscal Year End: December
Full Time Employees: 12
Back to stocks